New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
12:55 EDTGILD, ABT, ACHNAchillion drops after competitors report promising HCV data
Achillion (ACHN), which is developing a hepatitis C virus, or HCV, treatment, is retreating after two other companies reported that their HCV treatments had performed well in tests. Gilead (GILD) reported that it did not detect HCV in the RNA of 25 HCV patients four weeks after they were treated with the company's investigational drug. Meanwhile, Abbott (ABT) said that its HCV treatment, SVR12, had produced "high sustained viral response rates" in patients. In a note to investors earlier today, Deutsche Bank analyst Alethia Young wrote that she expects Gilead to obtain 65% of the HCV market, but she predicts that Achillion will garner a 15% share. Moreover, the analyst believes that Achillion's treatment is simpler and better than that of Abbott. She thinks that the decline in Achillion's stock today is overdone, and recommends buying the shares on weakness. Similarly, Wells Fargo analyst Brian Abraham believes that Achillion's data suggests that its treatment could be as good as or better than that of Abbott’s. Achillion is well-positioned to participate in the HCV market, and today's weakness has created an attractive entry point in the stock, he wrote. In early afternoon trading, Achillion slumped $1.06, or 11.76%, to $7.91.
News For ACHN;ABT;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
05:38 EDTABTAbbott announces results of naturally dissolving stent from ABSORB study
Subscribe for More Information
August 31, 2015
05:36 EDTABTStocks with implied volatility movement; MNKD ABT
Subscribe for More Information
August 27, 2015
13:42 EDTABTAnalyst says Abbott-St. Jude deal looks unlikely
Subscribe for More Information
12:41 EDTABTOn The Fly: Top stock stories at midday
Stocks began the session sharply higher, extending the rally that started yesterday. A number of factors may be contributors to today's strength, including China's government intervening in its market last night and pushing its key stock index up 5%, dovish comments made by N.Y. Fed President Bill Dudley yesterday regarding the potential for a September interest rate hike and an upward revision in the estimate of second quarter GDP growth. ECONOMIC EVENTS: In the U.S., the updated estimate of GDP growth showed the economy grew 3.7% in the second quarter, topping expectations for annualized growth to be revised up to 3.2% from the prior estimate of 2.3%. Personal consumption in the quarter rose 3.1%, matching expectations. 271,000 initial jobless claims were filed last week, versus expectations for 274,000 first-time claims. The NAR pending home sales index rose 0.5% in July, missing the expectation for an increase of 1%. In China, the Shanghai composite index rose 5.3%, stemming its recent string of down days, with media reports indicating that the government may have played a role by stepping in to buy stocks. COMPANY NEWS: Shares of St. Jude Medical (STJ) advanced 4.5% after the Financial Times reported, citing sources, that Abbott (ABT) is prepping a takeover offer that would value the medical device maker at $25B. An Abbott spokesperson, however, issued statements to Bloomberg, CNBC and the Wall Street Journal following the report to deny that it is pursuing a bid for St. Jude, which struck a deal in July to acquire fellow medical device manufacturer Thoratec (THOR) for $63.50 per share in cash, or $3.4B, net of cash acquired. Thoratec shares slid 0.5% near noon following the report, as investors may be concerned that the previously announced deal could be jeopardized if Abbott does in fact step in to the situation... Shares of Freeport-McMoRan (FCX) surged 28% this morning after the miner and oil explorer announced plans to cut spending and production, including plans to cut about 10% of employees and contractors at its U.S. mining operations. Freeport has lowered its 2016 capital expenditure budget to $4B, or approximately 29% lower than the $5.6B estimate it issued on July 23, which it said reflects "aggressive" actions in response to current market conditions. MAJOR MOVERS: Among the notable gainers was Movado (MOV), which gained 20% after the company reported better than expected second quarter results and backed its fiscal year earnings view. Also higher following its earnings report was Signet Jewelers (SIG), whose shares rose 13%. Another jeweler reporting earnings this morning, Tiffany (TIF), which slid 3% after the company lowered its fiscal year outlook. Among the other noteworthy losers following their earnings reports were Williams-Sonoma (WSM), which dropped 7%, and Dollar General (DG), which slipped 4%. INDEXES: Near midday, the Dow was up 311.33, or 1.91%, to 16,596.84, the Nasdaq was up 109.30, or 2.33%, to 4,806.83, and the S&P 500 was up 42.77, or 2.2%, to 1,983.28.
12:20 EDTABTDeutsche Bank says would have mixed view of Abbott-St. Jude deal
Deutsche Bank analyst Kristen Stewart said she would have a "somewhat mixed" view if Abbott (ABT) were in fact to pursue a deal to buy St. Jude Medical (STJ), as was raised as a possibility by a Financial Times report this morning. Stewart said the addition of St. Jude would "significantly" improve Abbott's Device division, specifically its vascular franchise, but she adds that the $25B bid discussed in the report would be "full value" for St. Jude and wonders if such a deal would be the most efficient use of capital for a diversified company like Abbott. The analyst said her view on each stock is unchanged overall at this point and she keeps her Buy rating on Abbott and Hold rating on St. Jude.
12:07 EDTABTAbbott bid for St. Jude doesn't seem likely, says Wells Fargo
Subscribe for More Information
09:26 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
07:57 EDTABTAbbott spokesman says company not making offer for St. Jude, Bloomberg reports
The spokesperson's statement to Bloomberg follows a report earlier this morning from Financial Times that claimed Abbott (ABT) is prepping a takeover offer for St. Jude Medical (STJ) that would value the latter at $25B.
07:51 EDTABTThoratec volatility low into report Abbott prepping offer for St. Jude Medical
Thoratec (THOR) September call option implied volatility is at 10, October is at 6; compared to its 52-week range of 8 to 54 suggesting decreasing price movement into reports Abbott (ABT) is preparing a bid for St. Jude Medical (STJ). In July St. Jude Medical and Thoratec approved an agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash. The deal is scheduled to close in Q4.
07:45 EDTABTAbbott volatility up into report prepping takeover offer for St. Jude Medical
Subscribe for More Information
07:39 EDTABTSt. Jude Medical volatility up, Abbott prepping $25B takeover offer FT reports
St. Jude Medical (STJ) September call option implied volatility is at 29, October is at 27; compared to its 52-week range of 17 to 36; suggesting slightly larger near term price movement into Abbott (ABT) is prepping a takeover offer that would value the company at $25B, sources tell The Financial Times.
06:57 EDTABTAbbott prepping $25B takeover offer for St. Jude Medical, FT reports
Subscribe for More Information
06:56 EDTABTAbbott prepping $25B takeover offer for St. Jude Medical, FT reports
Subscribe for More Information
August 26, 2015
17:06 EDTGILDGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
August 25, 2015
19:34 EDTGILDExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
August 24, 2015
13:36 EDTGILDBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 20, 2015
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
11:49 EDTACHNOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use